Webinars, Pharmaceutical

Accelerating the development of COVID vaccines and therapeutics

There are several key strategic decisions to be made in the rapid development of COVID-19 vaccines and treatments, including where to target drug delivery, the appropriate formulation, the correct drug delivery system and the best regulatory pathway. This webinar discusses these challenges from the perspective of nasal and respiratory drug delivery. As SARS-CoV-2 gains a foothold in the body via the ACE2 receptors located in the nose, nasopharynx and lungs, vaccine delivery to the respiratory tract could be highly advantageous. The pathophysiologic rationale of drug delivery targets in the upper and lower airways are considered and key attributes for classes of therapeutic compounds differentiated. This information provides a foundation for the selection of an appropriate drug delivery platform and to drive formulation development. A key goal is to highlight a pathway to rapidly develop a formulation and drug delivery system combination that allows clinical trials to start quickly. The acceleration of lead selection to mitigate risk, using novel in vitro deposition studies and regional deposition modeling, is discussed.

June 15, 2020 5:00 PM London / 12:00 PM New York 1 Hour
watch the webinar
Presented by Dr. Julie D. Suman Dr. Jag Shur
15 Jun 2020

Presented By

Dr. Julie D. Suman

PhD, President, Next Breath, an Aptar Pharma Company

Julie holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). She is a co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Julie is a Past-Chair of the AAPS Inhalation Technology Focus Group. She is also a licensed Maryland pharmacist. Julie has published her research in peer-reviewed journals, has presented during podium sessions at international meetings such as the FDA Visiting Professor Lecture Series, and has been an invited speaker at ANVISA in Brazil. Dr. Suman’s doctoral research, which focused on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by a research award presented at the International Society for Aerosols in Medicine, 2001.

Dr. Jag Shur

CEO, Nanopharm, an Aptar Pharma Company

Jag’s main area of research is investigation of the bioequivalence of orally inhaled and nasal drug products (OINDPs). The key theme of his research has been the development and application of novel tools to understand and quantify the microstructure of OINDPs. He began his career with Profile Drug Delivery (now Philips Respironics) where he developed liquid dose drug delivery systems for cystic fibrosis patients, and later went on to work for GlaxoSmithKline. Jag holds a BSc (Hons) in Chemistry and completed his PhD, entitled ‘Formulated Muco-Regulatory Agents in the Airways of Patients with Cystic Fibrosis’, at Portsmouth School of Pharmacy. Following this, he was a post-doctoral fellow at the London School of Pharmacy, investigating the fabrication of microparticles for vaccine delivery using supercritical fluid technology.

Start a Project With Us

We Thrive on Transforming Ideas into Opportunities – Let Yours be Next.

Contact a Pharma Expert

Request Access


Requesting access to Accelerating the development of COVID vaccines and therapeutics.

  • This field is for validation purposes and should be left unchanged.
Back To Top